

Purified anti-mouse F4/80 Antibody

Catalog# / Size	123101 / 50 µg 123102 / 500 µg
Clone	BM8
Regulatory Status	RUO
Other Names	EMR1, Ly71
Isotype	Rat IgG2a, κ
Description	F4/80 is a 160 kD glycoprotein. It is characterized as a member of the epidermal growth factor (EGF)-transmembrane 7 (TM7) family. F4/80, also known as EMR1 or Ly71, has been widely used as a murine macrophage marker, which is expressed on the majority of tissue macrophages including peritoneal macrophages, macrophages in lung, gut, thymus and red pulp of spleen (but not on the macrophages located in T cell areas of the spleen, lymph node and Peyer's patch), Kuffer cells, Langerhans cells, and bone marrow stromal cells. F4/80 has also been shown on a subset of dendritic cells. The biological ligand of F4/80 has not been identified, but it has been reported that F4/80 is required for induction of CD8 ⁺ T cell-mediated peripheral tolerance.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Murine macrophages
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C.
Application	FC - Quality tested IHC, WB - Reported in the literature, not verified in house
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes	Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections ^{1,2} and formalin-fixed paraffin-embedded sections ^{6,7} , Western blotting, and spatial biology (IBEX) ^{12,13} .
Application References	<ol style="list-style-type: none"> Schaller E, <i>et al.</i> 2002. <i>Mol. Cell. Biol.</i> 22:8035. (IHC) Stevceva L, <i>et al.</i> 2001. <i>BMC Clin Pathol.</i> 1:3. (IHC) Kobayashi M, <i>et al.</i> 2008. <i>J. Leukoc. Biol.</i> 83:1354. PubMed PoECKel D, <i>et al.</i> 2009. <i>J. Biol Chem.</i> 284:21077. PubMed Glass AM, <i>et al.</i> 2013. <i>J. Immunol.</i> 190:4830. PubMed Koehm S, <i>et al.</i> 2007. <i>J. Allergy Clin. Immunol.</i> 120:570. (IHC) Rankin AL, <i>et al.</i> 2010. <i>J. Immunol.</i> 184:1526. (IHC) Sasi SP, <i>et al.</i> 2014. <i>J Biol Chem.</i> 289:14178. PubMed Thakus VS, <i>et al.</i> 2014. <i>Toxicol Lett.</i> 230:322. PubMed Watson NB, <i>et al.</i> 2015. <i>J Immunol.</i> 194:2796. PubMed Hirakawa H, <i>et al.</i> 2015. <i>PLoS One.</i> 10:119360. PubMed Radtke AJ, <i>et al.</i> 2020. <i>Proc Natl Acad Sci U S A.</i> 117:33455-65. (SB) PubMed Radtke AJ, <i>et al.</i> 2022. <i>Nat Protoc.</i> 17:378-401. (SB) PubMed
(PubMed link indicates BioLegend citation)	

Product Citations

1. Hernández-Santana YE, *et al.* 2020. Life Sci Alliance. 3:00. [PubMed](#)
2. Rehrauer H, *et al.* 2018. Oncogene. 7:1487250. [PubMed](#)
3. Gomes AC, *et al.* 2019. J Immunol. 203:2485. [PubMed](#)
4. Dallari S, *et al.* 2017. Nat Commun. 8:14830. [PubMed](#)
5. Arnold IC, *et al.* 2019. PLoS Pathog. 15:e1007866. [PubMed](#)
6. Elshal M, *et al.* 2022. Arch Pharm Res. . [PubMed](#)
7. Paterson MJ, *et al.* 2020. PLoS Pathog. 16:e1008733. [PubMed](#)
8. Volmari A, *et al.* 2021. Hepatol Commun. 5:2104. [PubMed](#)
9. Reglero-Real N, *et al.* 2021. Immunity. .: [PubMed](#)
10. Kaneko T, *et al.* 2012. J Immunol. 188:5397. [PubMed](#)
11. Vitiello GA, *et al.* 2018. Clin Cancer Res. 24:972. [PubMed](#)
12. Burrello C, *et al.* 2018. Front Med (Lausanne). 5:21. [PubMed](#)
13. Shirakawa K, *et al.* 2017. PLoS One. 12:e0186303. [PubMed](#)
14. Gray ME, *et al.* 2018. J Biomed Mater Res B Appl Biomater. 107(5):1620-1633. [PubMed](#)
15. Wang B *et al.* 2018. Cell stem cell. 22(2):206-220 . [PubMed](#)
16. Zou B, *et al.* 2017. PLoS Pathogens. 13(6):e1006436. [PubMed](#)
17. Cheng AA, *et al.* 2021. Am J Physiol Endocrinol Metab. 320:E438. [PubMed](#)
18. Nobs SP, *et al.* 2021. J Allergy Clin Immunol. . [PubMed](#)
19. Khan KA, *et al.* 2020. NPJ Breast Cancer. 6:29. [PubMed](#)
20. Maestro S, *et al.* 2021. Viruses. 13: . [PubMed](#)
21. Chen YS, *et al.* 2019. Cells. 8:3. [PubMed](#)
22. Merz SF, *et al.* 2019. Nat Commun. 10:2312. [PubMed](#)
23. Karnezis T *et al.* 2019. Cancer Res. 79(7):1558-1572 . [PubMed](#)
24. Rieck M, *et al.* 2017. Eur J Immunol. 47:677. [PubMed](#)
25. Wang W, *et al.* 2018. Cancer Cell. 34:757. [PubMed](#)
26. Duvvuri M, *et al.* 2019. Biomater Sci. 7:1863. [PubMed](#)
27. Arnold IC, *et al.* 2018. J Exp Med. 215:2055. [PubMed](#)
28. Accarias S, *et al.* 2020. J Cell Sci. 133:. [PubMed](#)
29. Prado C, *et al.* 2021. J Neuroinflammation. 18:292. [PubMed](#)
30. Lu L, *et al.* 2022. Sci Rep. 12:931. [PubMed](#)
31. Yang J, *et al.* 2022. Biosci Rep. .: [PubMed](#)
32. Elshal M, *et al.* 2022. Inflammopharmacology. .: [PubMed](#)
33. Altshuler A, *et al.* 2021. Cell Stem Cell. 28(7):1248-1261.e8. [PubMed](#)
34. Yuan Q, *et al.* 2021. Cell Reports. 34(5):108724. [PubMed](#)
35. Cao Q, *et al.* 2018. Am J Physiol Renal Physiol. 314:F561. [PubMed](#)
36. Chen J, *et al.* 2018. Hypertension. 71:877. [PubMed](#)
37. Weis S *et al.* 2017. Cell. 169(7):1263-1275 . [PubMed](#)
38. De Vlaeminck Y, *et al.* 2020. Cancers (Basel). 12:. [PubMed](#)
39. Xu Q, *et al.* 2021. Front Physiol. 12:732084. [PubMed](#)
40. Kennedy CL, *et al.* 2021. Toxics. 9:. [PubMed](#)
41. Goswami S, *et al.* 2021. J Cell Physiol. 236:8148. [PubMed](#)
42. Cai Z, *et al.* 2021. Front Immunol. 12:646384. [PubMed](#)
43. Nagatake T, *et al.* 2022. Mucosal Immunol. 15:289. [PubMed](#)
44. Wada N, *et al.* 2020. Mol Metab. 37:100988. [PubMed](#)
45. Malsy J, *et al.* 2020. Elife. 9:00. [PubMed](#)
46. Cozzitorto C, *et al.* 2020. Developmental Cell. 55(2):150-162.e6. [PubMed](#)
47. Wang Y, *et al.* 2021. Cancer Cell. .: [PubMed](#)
48. Ma F, *et al.* 2020. Sci Signal. :13. [PubMed](#)
49. Motoyama S, *et al.* 2020. Cells. :9. [PubMed](#)
50. Cheng Y, *et al.* 2018. J Exp Med. 215:2919. [PubMed](#)
51. Arimura K, *et al.* 2017. Mucosal Immunol. 1.08125. [PubMed](#)
52. Duarte N, *et al.* 2018. Hepatol Commun. 0.833333333. [PubMed](#)
53. Liu T, *et al.* 2020. Sci Adv. 6:eaay1497. [PubMed](#)
54. Cvetanova B, *et al.* 2021. Int J Mol Sci. 22: . [PubMed](#)
55. Joseph R, *et al.* 2021. Br J Cancer. 125:176. [PubMed](#)
56. Huang YL, *et al.* 2021. Antioxidants (Basel). 10:. [PubMed](#)
57. Peng J, *et al.* 2020. Toxicol Res (Camb). 9:609. [PubMed](#)
58. Huang YL, *et al.* 2021. Aging Cell. 20:e13523. [PubMed](#)
59. Stefanescu C, *et al.* 2021. Front Oncol. 11:765151. [PubMed](#)
60. Kuziel G, *et al.* 2020. Cancers (Basel). 12:00. [PubMed](#)
61. Hayakawa K, *et al.* 2016. J Cereb Blood Flow Metab. 36: 781-793. [PubMed](#)
62. Do DC, *et al.* 2019. JCI Insight. 4:e126832. [PubMed](#)
63. Kitai Y, *et al.* 2017. J Immunol. 198:1649. [PubMed](#)
64. Nakamizo S, *et al.* 2017. Sci Rep. . 10.1038/s41598-017-14292-1. [PubMed](#)
65. Yang M, *et al.* 2020. Oncoimmunology. 9:1708064. [PubMed](#)
66. Miyake M, *et al.* 2021. iScience. 24:103448. [PubMed](#)
67. Billerhart M, *et al.* 2021. Mol Ther Oncolytics. 23:192. [PubMed](#)
68. Sun H, *et al.* 2018. J Cell Biol. 217:1453. [PubMed](#)
69. Bálint L, *et al.* 2020. Front Immunol. 2.529861111. [PubMed](#)
70. Khan KA, *et al.* 2020. NPJ Breast Cancer. 6:29. [PubMed](#)
71. O'Dea KP, *et al.* 2020. J Extracell Vesicles. 9:1706708. [PubMed](#)
72. Matsuhiro T, *et al.* 2021. Biochem Biophys Rep. 28:101118. [PubMed](#)
73. Chen L, *et al.* 2020. Front Immunol. 11:584458. [PubMed](#)
74. Li Y, *et al.* 2021. Cardiovasc Res. 890:117. [PubMed](#)
75. Cassidy LD, *et al.* 2018. Autophagy. 1.455555556. [PubMed](#)
76. Seelige R, *et al.* 2018. Sci Rep. 8:13670. [PubMed](#)
77. Tsujinaka H, *et al.* 2020. Nat Commun. 0.940277778. [PubMed](#)
78. Stacey MA, *et al.* 2017. J Clin Invest. 127:1463. [PubMed](#)
79. Rätsep MT, *et al.* 2018. Am J Physiol Lung Cell Mol Physiol. 315:L977. [PubMed](#)
80. Matsuo R, *et al.* 2022. JID Innov. 2:100141. [PubMed](#)

81. Sun Y, *et al.* 2022. *Nat Commun.* 13:3916. [PubMed](#)
82. Oba T, *et al.* 2021. *J Immunother Cancer.* 9:. [PubMed](#)
83. Yang K, *et al.* 2017. *Nature.* 548:602. [PubMed](#)
84. Mainini F, *et al.* 2018. *Nucleic Acid Ther.* 28:225. [PubMed](#)
85. Kobayashi M, *et al.* 2008. *J Leukoc Biol.* 83:1354. [PubMed](#)
86. Andersson &, *et al.* 2011. *Clin Cancer Res.* 3.25. [PubMed](#)
87. Sato Y, *et al.* 2021. *BMC Cancer.* 21:1222. [PubMed](#)
88. Wang Y, *et al.* 2021. *Sci Transl Med.* 13:. [PubMed](#)
89. Shokirova H, *et al.* 2021. *Sci Rep.* 11:8647. [PubMed](#)
90. Wei S, *et al.* 2019. *Virulence.* 0.588888889. [PubMed](#)
91. Borges TJ, *et al.* 2018. *Nat Commun.* 9:3482. [PubMed](#)
92. Hoves S, *et al.* 2018. *J Exp Med.* 215:859. [PubMed](#)
93. Mueller–Ortiz SL, *et al.* 2019. *J Immunol.* 203:2701. [PubMed](#)
94. Kaufmann B, *et al.* 2022. *EMBO Rep.* 23:e54446. [PubMed](#)
95. Hu G, *et al.* 2021. *Nat Commun.* 12:773. [PubMed](#)
96. Tsai F, *et al.* 2017. *J Exp Med.* 214:3753. [PubMed](#)
97. Davies CL, *et al.* 2019. *Front Immunol.* 10:1048. [PubMed](#)
98. Shin J, *et al.* 2018. *Diabetes.* 67:1068. [PubMed](#)
99. Janardhan KS, *et al.* 2018. *Toxicol Pathol.* 46:488. [PubMed](#)
100. Johnson SA, *et al.* 2021. *Eur J Immunol.* 51:3228. [PubMed](#)
101. Yoon S, *et al.* 2020. *Antioxidants (Basel).* 10:. [PubMed](#)
102. Tao H, *et al.* 2021. *Front Immunol.* 12:623280. [PubMed](#)
103. Li X, *et al.* 2020. *Nat Commun.* 4.877777778. [PubMed](#)
104. Piao Y, *et al.* 2016. *Neuro Oncology.* 18: 1230 - 1241. [PubMed](#)
105. PoECKel D, *et al.* 2009. *J Biol Chem.* 284:21077. [PubMed](#)
106. Daley D, *et al.* 2017. *Nat Med.* 23:556. [PubMed](#)
107. Luo J *et al.* 2018. *Immunity.* 49(1):107-119 . [PubMed](#)
108. Defaye M, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 13:977. [PubMed](#)
109. Ejima R, *et al.* 2021. *Nutrients.* 13:. [PubMed](#)
110. Jiang Y, *et al.* 2021. *Cell Death Differ.* 28:3009. [PubMed](#)
111. Wu Y, *et al.* 2020. *Biol Reprod.* 1213:102. [PubMed](#)
112. Gubin MM, *et al.* 2018. *Cell.* 175:1014. [PubMed](#)
113. Veremeyko T, *et al.* 2019. *J Neurosci Res.* 97:162. [PubMed](#)
114. Fino KK, *et al.* 2017. *Sci Rep.* 5.334722222. [PubMed](#)
115. Jokinen MP, *et al.* 2017. *Toxicol Pathol.* 45:774. [PubMed](#)
116. Ford J, *et al.* 2019. *Front Immunol.* 2.502083333. [PubMed](#)
117. Goh W, *et al.* 2020. *Cell Rep.* 33:108285. [PubMed](#)
118. Sasi S, *et al.* 2014. *J Biol Chem.* 289:14178. [PubMed](#)
119. Kim D, *et al.* 2019. *Immune Netw.* 19:e32. [PubMed](#)
120. Moon H, *et al.* 2019. *Nat Commun.* 10:2225. [PubMed](#)
121. Levy BD, *et al.* 2020. *J Allergy Clin Immunol.* 145:335. [PubMed](#)
122. Hosomi K, *et al.* 2022. *Nat Commun.* 13:4477. [PubMed](#)
123. Seo SU, *et al.* 2021. *Front Immunol.* 12:697162. [PubMed](#)
124. Burns K, *et al.* 2012. *Endocrinology.* 153:3960. [PubMed](#)
125. Toyohara T, *et al.* 2020. *Cell Stem Cell.* 27:147. [PubMed](#)
126. Akiel M, *et al.* 2017. *Cancer Res.* 77:4014. [PubMed](#)
127. Lever JM, *et al.* 2019. *JCI Insight.* 4:e125503. [PubMed](#)
128. Wang Y, *et al.* 2019. *Biomed Res Int.* 2019:5756189. [PubMed](#)
129. Hong JE, *et al.* 2019. *Front Microbiol.* 0.727083333. [PubMed](#)
130. Jiao S, *et al.* 2020. *Cell.* 179(5):1177-1190.e13.. [PubMed](#)
131. Watson N, *et al.* 2015. *J Immunol.* 194:2796. [PubMed](#)
132. McArthur S, *et al.* 2020. *J Clin Invest.* 130:1156. [PubMed](#)
133. Dyrna F, *et al.* 2018. *Am J Sports Med.* 46:3511. [PubMed](#)
134. Liu J, *et al.* 2022. *Stem Cell Res Ther.* 13:247. [PubMed](#)
135. Liu J, *et al.* 2022. *Small.* 18:e2106172. [PubMed](#)
136. Li X, *et al.* 2021. *Eur J Immunol.* 51:2452. [PubMed](#)
137. Yang CC, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
138. Um HN, *et al.* 2021. *Cell Death Dis.* 12:243. [PubMed](#)
139. Thakur V, *et al.* 2014. *Toxicol Lett.* 230:322. [PubMed](#)
140. Quilichini E, *et al.* 2019. *Cell Mol Gastroenterol Hepatol.* 0.671527778. [PubMed](#)
141. Satoh–Takayama N, *et al.* 2020. *Immunity.* 52(4):635-649. [PubMed](#)
142. Burger ML, *et al.* 2021. *Cell.* 184:4996. [PubMed](#)
143. Yi X, *et al.* 2021. *J Bone Miner Res.* 36:2426. [PubMed](#)
144. Wang Y, *et al.* 2021. *Nat Commun.* 0.570833333. [PubMed](#)
145. Kikuchi N, *et al.* 2011. *Am J Respir Cell Mol Biol.* 45:600. [PubMed](#)
146. Hunt LC, *et al.* 2021. *Cell Rep.* 37:109971. [PubMed](#)
147. Nagatake T, *et al.* 2021. *Sci Rep.* 11:10426. [PubMed](#)
148. Rios–Doria J, *et al.* 2017. *Cancer Res.* 77:2686. [PubMed](#)
149. Zhang N, *et al.* 2021. *Proc Natl Acad Sci U S A.* 118:. [PubMed](#)
150. Song M, *et al.* 2020. *Nat Commun.* 11:6298. [PubMed](#)
151. Dubik M, *et al.* 2021. *Front Neurosci.* 15:682451. [PubMed](#)
152. Baluk P, *et al.* 2022. *Methods Mol Biol.* 2441:115. [PubMed](#)
153. Kang SH, *et al.* 2018. *Oncoimmunology.* 8:e1515057. [PubMed](#)
154. Ito Y, *et al.* 2018. *J Exp Med.* 215:2617. [PubMed](#)
155. Campbell KM, *et al.* 2019. *Cell Rep.* 28:1526. [PubMed](#)
156. Ireland L, *et al.* 2018. *Oncogene.* 293:4244. [PubMed](#)
157. Sutiwisesak R, *et al.* 2020. *PLoS Pathog.* 16:e1009000. [PubMed](#)

Antigen Details

Structure	EGF-TM7 family member, 160 kD glycoprotein
Distribution	Majority of tissue macrophages including peritoneal macrophages, macrophages in lung, gut, thymus and red pulp of spleen, Kuffer cells, Langerhans cells, bone marrow stromal cells, and a subset of dendritic cells
Function	Induction of immunological tolerance
Cell Type	Dendritic cells, Langerhans cells, Macrophages, Tregs
Biology Area	Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience
Antigen References	<ol style="list-style-type: none"> 1. Austy JM and Gordon S. 1981. <i>Eur. J. Immunol.</i> 11:805. 2. Hume DA, <i>et al.</i> 1983. <i>J. Exp. Med.</i> 158:1522. 3. Ruedl C, <i>et al.</i> 1996. <i>Eur. J. Immunol.</i> 26:1801. 4. McKnight AJ, <i>et al.</i> 1996. <i>J. Biol. Chem.</i> 271:486. 5. Lin HH, <i>et al.</i> 2005. <i>J. Exp. Med.</i> 201:1615.
Gene ID	13733

Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

Brilliant Violet 605™ anti-mouse F4/80, Purified anti-mouse F4/80, Biotin anti-mouse F4/80, FITC anti-mouse F4/80, PE anti-mouse F4/80, PE/Cyanine5 anti-mouse F4/80, PE/Cyanine7 anti-mouse F4/80, APC anti-mouse F4/80, APC/Cyanine7 anti-mouse F4/80, Alexa Fluor® 488 anti-mouse F4/80, Alexa Fluor® 647 anti-mouse F4/80, Pacific Blue™ anti-mouse F4/80, PerCP anti-mouse F4/80, PerCP/Cyanine5.5 anti-mouse F4/80, Alexa Fluor® 700 anti-mouse F4/80, Brilliant Violet 421™ anti-mouse F4/80, Brilliant Violet 510™ anti-mouse F4/80, Alexa Fluor® 594 anti-mouse F4/80, Brilliant Violet 785™ anti-mouse F4/80, Purified anti-mouse F4/80 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse F4/80, Brilliant Violet 650™ anti-mouse F4/80, Brilliant Violet 711™ anti-mouse F4/80, APC/Fire™ 750 anti-mouse F4/80, TotalSeq™-A0114 anti-mouse F4/80, TotalSeq™-B0114 anti-mouse F4/80, TotalSeq™-C0114 anti-mouse F4/80, Spark YG™ 570 anti-mouse F4/80, KIRAVIA Blue 520™ anti-mouse F4/80, Ultra-LEAF™ Purified anti-mouse F4/80, APC/Fire™ 810 anti-mouse F4/80, Spark NIR™ 685 anti-mouse F4/80

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
 Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587